Immix Biopharma has reported early positive interim data from its ongoing Phase Ib/IIa dose escalation clinical trial IMMINENT-01 of IMX-110 for the treatment of advanced metastatic colorectal cancer.

The trial evaluated the combination of tissue specific therapeutic IMX-110 with BeiGene/Novartis’ anti-PD-1 antibody tislelizumab in patients with advanced solid tumours.

Cohorts of three patients will receive escalating IMX-110 doses in the Phase Ib study until the maximum tolerated dose is reached and the recommended dose for Phase II is determined.

Two out of two first evaluable patients who received the lowest dose of IMX-110 demonstrated a 100% tumour shrinkage at two months.

No dose limiting toxicities have been observed in the first treated group enabling Immix to enrol three patients for the next cohort receiving a higher combined dose .

Phase IIa study expects to enrol 30 patients with solid tumour indications.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Evaluation of safety and identifying the maximum tolerated dose and recommending Phase II dose of IMX-110 plus anti-PD-1 antibody tislelizumab are the primary endpoints of the study.

Secondary endpoints include evaluating the pharmacokinetics and preliminary efficacy of IMX-110 plus anti-PD-1 antibody tislelizumab.

Immix Biopharma CEO Ilya Rachman said: “These initial results potentially validate the scientific rationale for the promise of IMX-110 to unlock our immune system’s ability to fight cancer.”